A study by Stig Mortensen and colleagues from Aahus University Hospital Skejby in Denmark revealed that diabetic patients with coronary artery disease (CAD) have reduced platelet response to aspirin.
Study:
The researchers studied 85 diabetic and 92 nondiabetic CAD patients. All the 177 patients taking 75 mg/day non-enteric coated aspirin had platelet aggregation evaluated using arachidonic acid 0.5 and 1.0 mM and platelet activation assessed by soluble (s)P-selectin.
Result:
The study revealed that patients with diabetes had significantly higher levels of platelet aggregation and activation compared with nondiabetics.
The researchers claim that "these findings may partly explain the reduced cardiovascular protection from aspirin in diabetic patients."
The authors concluded: "Several mechanisms may explain the reduced response of diabetic platelets to aspirin. Hyperglycemia together with dyslipidemia and insulin resistance in diabetic patients may all affect the response to antiplatelet drugs.”
"Hyperglycemia may cause a competition between acetylation and glycation of platelet proteins… Diabetics might also have an increased platelet turnover and be hypersensitive to pro-aggregatory agonists causing an increased platelet activation and aggregation.”
No comments:
Post a Comment